AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.
Patient Care Online
AHA Scientific Sessions 2019: Early results from the EVAPORATE study suggest promise for icosapent ethyl as add-on therapy in patients with high TGs already taking statins.
AHA Scientific Sessions 2019: Semi-annual injection of the novel agent inclisiran in the ORION-10 trial decreased LDL-C by 56% in patients with ASCVD on maximal statin therapy.
AHA Scientific Sessions 2019: Post-TAVR use of rivaroxaban is not recommended for routine use among patients with no indication for anticoagulation.
The cost associated with smoking cigarettes doesn't end with the price of a pack. A new study looks deeper in all 50 states plus DC.
AHA Scientific Sessions 2019: In SIHD patients with moderate-severe ischemia, initial revascularization + OMT compared to OMT alone did not reduce the risk for adverse CV outcomes
The burden of poor mental health among CF patients is significant and impacts all aspects of disease management. Test yourself on international best practices for screening and treatment.
Researchers of the new study being presented at the upcoming AHA 2019 Scientific Sessions highlight key inequalities related to disparities in the vaccination rates.
Depression in people with cystic fibrosis is 2 times higher than in the general population and among their caretakers, 3 times higher. The toll on treatment adherence is significant.
After bariatric surgery, risk of a cerebrovascular event among obese patients was found to be signficantly lower than among matched controls. An AHA 2019 preview.